| Year |
Citation |
Score |
| 2021 |
Mahmood RD, Shaw D, Descamps T, Zhou C, Morgan RD, Mullamitha S, Saunders M, Mescallado N, Backen A, Morris K, Little RA, Cheung S, Watson Y, O'Connor JPB, Jackson A, et al. Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. Bmc Cancer. 21: 354. PMID 33794823 DOI: 10.1186/s12885-021-08097-9 |
0.301 |
|
| 2016 |
Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, ... ... Saunders MP, et al. Clinical development of new drug-radiotherapy combinations. Nature Reviews. Clinical Oncology. PMID 27245279 DOI: 10.1038/nrclinonc.2016.79 |
0.302 |
|
| 2013 |
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, ... ... Saunders M, et al. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 72: 1343-52. PMID 24141375 DOI: 10.1007/s00280-013-2320-9 |
0.388 |
|
| 2003 |
Patterson AV, Saunders MP, Greco O. Prodrugs in genetic chemoradiotherapy. Current Pharmaceutical Design. 9: 2131-54. PMID 14529410 DOI: 10.2174/1381612033454117 |
0.395 |
|
| Show low-probability matches. |